Sociodemographic and clinical characteristics of persons who experienced spontaneous hepatitis C viral clearance.
Adolescent
Adult
Black or African American
Aged
California
/ epidemiology
Female
Hepacivirus
/ genetics
Hepatitis C
/ diagnosis
Hepatitis C Antibodies
/ blood
Humans
Male
Middle Aged
RNA, Viral
/ blood
Remission, Spontaneous
Renal Insufficiency, Chronic
/ diagnosis
Retrospective Studies
White People
Young Adult
Epidemiology
Hepatitis C
Spontaneous clearance
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
15 Jul 2019
15 Jul 2019
Historique:
received:
17
08
2018
accepted:
26
06
2019
entrez:
17
7
2019
pubmed:
17
7
2019
medline:
26
9
2019
Statut:
epublish
Résumé
In the United States Hepatitis C virus (HCV) viral clearance is estimated to range between 20 and 30%. The objective of this study was to estimate the frequency of HCV clearance and identify correlates of viral clearance among patients newly identified as HCV antibody positive in a large urban health system in Los Angeles, California. We identified patients between November 2015 and September 2017 as part of a newly implemented HCV screening and linkage-to-care program at University of California Los Angeles (UCLA) Health System. All patients were eligible for screening, though there were additional efforts to screen patients born between 1945 and 1965. We reviewed Medical records to categorize anti-HCV antibody positive patients as having spontaneously cleared HCV infection (HCV RNA not detected) or not (HCV RNA detected). We excluded those with a prior history of anti-HCV positivity or history of HCV treatment. We compared differences between those with and without detectable HCV RNA using chi-square test, Fisher's exact test, and t-test as appropriate. We assessed factors associated with HCV clearance using logistic regression analysis. Among the 320 patients included in this study, 56% were male. Baby boomers (52-72 years of age) comprised the single largest age group (62%). We found spontaneous HCV clearance in 58% (n = 185). HCV viral clearance was slightly higher among women as compared to men (63% vs. 53%; p value = 0.07) and varied by race/ethnicity: clearance among Blacks/African Americans was 37% vs. 58% among whites (p value = 0.02). After adjusting for age, race/ethnicity, and sex we found that those diagnosed with chronic kidney disease had a tendency of decreased HCV viral clearance (adjusted OR = 0.34; 95% CI 0.14-1.03). Of those patients newly identified as anti-HCV positive, 58% had cleared HCV virus, while the rest showed evidence of active infection. In addition, we found that clearance varied by race/ethnicity and clinical characteristics.
Sections du résumé
BACKGROUND
BACKGROUND
In the United States Hepatitis C virus (HCV) viral clearance is estimated to range between 20 and 30%. The objective of this study was to estimate the frequency of HCV clearance and identify correlates of viral clearance among patients newly identified as HCV antibody positive in a large urban health system in Los Angeles, California.
METHODS
METHODS
We identified patients between November 2015 and September 2017 as part of a newly implemented HCV screening and linkage-to-care program at University of California Los Angeles (UCLA) Health System. All patients were eligible for screening, though there were additional efforts to screen patients born between 1945 and 1965. We reviewed Medical records to categorize anti-HCV antibody positive patients as having spontaneously cleared HCV infection (HCV RNA not detected) or not (HCV RNA detected). We excluded those with a prior history of anti-HCV positivity or history of HCV treatment. We compared differences between those with and without detectable HCV RNA using chi-square test, Fisher's exact test, and t-test as appropriate. We assessed factors associated with HCV clearance using logistic regression analysis.
RESULTS
RESULTS
Among the 320 patients included in this study, 56% were male. Baby boomers (52-72 years of age) comprised the single largest age group (62%). We found spontaneous HCV clearance in 58% (n = 185). HCV viral clearance was slightly higher among women as compared to men (63% vs. 53%; p value = 0.07) and varied by race/ethnicity: clearance among Blacks/African Americans was 37% vs. 58% among whites (p value = 0.02). After adjusting for age, race/ethnicity, and sex we found that those diagnosed with chronic kidney disease had a tendency of decreased HCV viral clearance (adjusted OR = 0.34; 95% CI 0.14-1.03).
CONCLUSION
CONCLUSIONS
Of those patients newly identified as anti-HCV positive, 58% had cleared HCV virus, while the rest showed evidence of active infection. In addition, we found that clearance varied by race/ethnicity and clinical characteristics.
Identifiants
pubmed: 31307403
doi: 10.1186/s12879-019-4223-9
pii: 10.1186/s12879-019-4223-9
pmc: PMC6632203
doi:
Substances chimiques
Hepatitis C Antibodies
0
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
626Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR000122
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001882
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH058107
Pays : United States
Organisme : Gilead Sciences
ID : 20173211
Références
Trends Immunol. 2001 Nov;22(11):633-40
pubmed: 11698225
J Infect Dis. 2004 May 15;189(10):1846-55
pubmed: 15122521
Blood. 2006 Feb 1;107(3):892-7
pubmed: 16204310
J Viral Hepat. 2006 Jan;13(1):34-41
pubmed: 16364080
Transfusion. 2006 Mar;46(3):469-75
pubmed: 16533292
AIDS. 2007 Jul 31;21(12):1631-6
pubmed: 17630559
Can J Gastroenterol. 2007 Jul;21(7):447-51
pubmed: 17637948
Hepatology. 2007 Aug;46(2):350-8
pubmed: 17659573
Genome Biol. 2007;8(9):R189
pubmed: 17854483
World J Gastroenterol. 2008 Mar 28;14(12):1878-84
pubmed: 18350626
Nature. 2009 Sep 17;461(7262):399-401
pubmed: 19684573
Nature. 2009 Oct 8;461(7265):798-801
pubmed: 19759533
J Biol Chem. 2010 Jul 23;285(30):22741-7
pubmed: 20457596
Curr Dir Psychol Sci. 2009 Jun 1;18(3):132-137
pubmed: 21243077
J Med Virol. 2012 Feb;84(2):235-41
pubmed: 22170543
Hepatology. 2012 Oct;56(4):1214-22
pubmed: 22505144
PLoS One. 2012;7(5):e37054
pubmed: 22649509
Blood. 1990 Dec 15;76(12):2421-38
pubmed: 2265240
Dig Dis Sci. 2013 May;58(5):1341-8
pubmed: 23179159
Ann Intern Med. 2013 Jan 15;158(2):101-8
pubmed: 23183613
Gene. 2013 Apr 15;518(2):479-82
pubmed: 23266640
BMC Med. 2013 Jan 08;11:6
pubmed: 23298311
Saudi J Gastroenterol. 2013 Mar-Apr;19(2):81-5
pubmed: 23481134
J Gastroenterol Hepatol. 2015 May;30(5):879-84
pubmed: 23808794
Hepatology. 2014 Jan;59(1):109-20
pubmed: 23908124
Am J Public Health. 2013 Oct;103 Suppl 1:S84-92
pubmed: 23927506
Hepatology. 2014 Dec;60(6):2127-8
pubmed: 24715633
World J Hepatol. 2015 Jan 27;7(1):78-92
pubmed: 25624999
J Infect Dis. 2015 Nov 1;212(9):1407-19
pubmed: 25883387
J Hosp Med. 2015 Aug;10(8):510-6
pubmed: 26033458
Clin Infect Dis. 2015 Nov 1;61(9):1381-8
pubmed: 26175521
Semin Dial. 2016 Jan-Feb;29(1):5-6
pubmed: 26781743
BMC Gastroenterol. 2016 Apr 04;16:45
pubmed: 27044402
J Hepatol. 2016 Aug;65(2):266-72
pubmed: 27155531
Public Health Rep. 2016 May-Jun;131 Suppl 2:49-56
pubmed: 27168662
Infect Agent Cancer. 2016 May 16;11:23
pubmed: 27186234
Drug Alcohol Depend. 2016 Dec 01;169:156-162
pubmed: 27816863
Blood Purif. 2017;43(1-3):206-209
pubmed: 28114144
J Adv Res. 2017 Mar;8(2):113-130
pubmed: 28149647
Open Forum Infect Dis. 2017 Jun 16;4(2):ofx090
pubmed: 28638847
Hepatology. 2017 Dec;66(6):1805-1813
pubmed: 28714196
Open Forum Infect Dis. 2017 May 27;4(3):ofx109
pubmed: 28752101
J Viral Hepat. 2018 Jun;25(6):680-698
pubmed: 29345844